Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Nestor R. Ramos"'
Autor:
Hong Yuen Wong, Anthony D. Sung, Katherine E. Lindblad, Sheenu Sheela, Gregory W. Roloff, David Rizzieri, Meghali Goswami, Matthew P. Mulé, Nestor R. Ramos, Jingrong Tang, Julie Thompson, Christin B. DeStefano, Kristi Romero, Laura W. Dillon, Dong-Yun Kim, Catherine Lai, Christopher S. Hourigan
Publikováno v:
Frontiers in Oncology, Vol 8 (2019)
Measurable residual disease (MRD) testing after initial chemotherapy treatment can predict relapse and survival in acute myeloid leukemia (AML). However, it has not been established if repeat molecular or genetic testing during chemotherapy can offer
Externí odkaz:
https://doaj.org/article/fa6ebebba15a441496da6f117f43dcad
Autor:
Anthony D. Sung, Laura W. Dillon, Meghali Goswami, Jingrong Tang, Hong Yuen Wong, Sheenu Sheela, Kristi Romero, Catherine Lai, David A. Rizzieri, Matthew P. Mulé, Nestor R. Ramos, Katherine E. Lindblad, Dong Yun Kim, Christopher S. Hourigan, Christin B. DeStefano, Gregory W. Roloff, Julie D. Thompson
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 8 (2019)
Frontiers in Oncology, Vol 8 (2019)
PURPOSEMeasurable residual disease (MRD) testing after initial chemotherapy treatment can predict relapse and survival in AML. However, it has not been established if repeat molecular or genetic testing during chemotherapy can offer information regar
Publikováno v:
Journal of Clinical Medicine
Journal of Clinical Medicine, Vol 4, Iss 4, Pp 665-695 (2015)
Journal of Clinical Medicine, Vol 4, Iss 4, Pp 665-695 (2015)
The limited sensitivity of the historical treatment response criteria for acute myeloid leukemia (AML) has resulted in a different paradigm for treatment compared with most other cancers presenting with widely disseminated disease. Initial cytotoxic
Autor:
Charalambos Andreadis, Brent L. Wood, Christopher S. Hourigan, Aaron C Logan, Lloyd E. Damon, Gabriel N. Mannis, Thomas G. Martin, Matthew P. Mulé, Jimmy Hwang, Jerald P. Radich, Nestor R. Ramos
Publikováno v:
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, vol 22, iss 11
We report here the largest study to date of adult patients with acute myeloid leukemia (AML) tested for measurable residual disease (MRD) at the time of autologous hematopoietic cell transplantation (auto-HCT). Seventy-two adult patients who underwen
Autor:
Christopher S. Hourigan, Catherine Lai, Jerald P. Radich, Brent L. Wood, Lloyd E. Damon, Aaron C Logan, Matthew P. Mulé, Charalambos Andreadis, Gabriel N. Mannis, Michael Flanders, Thomas G. Martin, Nestor R. Ramos
Publikováno v:
Blood. 126:4350-4350
While commonly used in other hematological malignancies, high dose chemotherapy followed by autologous hematopoietic cell transplantation (auto-HCT) has not been widely adopted in acute myeloid leukemia (AML) due to concerns regarding high post-trans